Praxis terminates $250M Jefferies ATM, enters new $250M ATM with TD Cowen

Praxis Precision Medicines, Inc.

Terminated 2024 Sales Agreement with Jefferies effective Sept 2, 2025; no penalties.
Previously sold 1,368,176 shares for ~$86.2M gross proceeds under that agreement.
Entered new 2025 Sales Agreement with TD Cowen for up to $250M in at-the-market offerings.
TD Cowen will receive a commission of up to 3.0% of gross proceeds from sales.
New ATM will be made under existing S-3ASR registration statement.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.